• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

革新三阴性乳腺癌的治疗:利用外泌体微小RNA的力量进行靶向治疗。

Revolutionizing treatment for triple-negative breast cancer: Harnessing the power of exosomal miRNAs for targeted therapy.

作者信息

Jalil Abduladheem Turki, Jehad Muhanad Tareq, Al-Ameer Lubna R, Khallawi Anwar Qasim, Essa Israa M, Merza Muna S, Zabibah Rahman S, Al-Hili Farah

机构信息

College of Medicine, University of Thi-Qar, Al-Nasiriyah, Thi-Qar, Iraq.

College of Dentistry, Al-Esraa University, Baghdad, Iraq.

出版信息

Pathol Res Pract. 2023 Oct;250:154825. doi: 10.1016/j.prp.2023.154825. Epub 2023 Sep 16.

DOI:10.1016/j.prp.2023.154825
PMID:37769396
Abstract

Triple-negative breast cancer (TNBC) represents a challenging and aggressive form of breast cancer associated with limited treatment options and poor prognosis. Although chemotherapy is a primary therapeutic approach, drug resistance often hinders treatment success. However, the expanding knowledge of TNBC subtypes and molecular biology has paved the way for targeted therapies. Notably, exosomes (extracellular vesicles) have emerged as crucial carriers of tumorigenic factors involved in oncogenesis and drug resistance, facilitating cell-to-cell communication and offering potential as self-delivery systems. Among the cargo carried by exosomes, microRNAs (miRNAs) have gained attention due to their ability to mediate epigenetic changes in recipient cells upon transfer. Research has confirmed dysregulation of exosomal miRNAs in breast cancer cells compared to healthy cells, establishing them as promising biomarkers for cancer diagnosis and prognosis. In this comprehensive review, we summarize the latest research findings that underscore the diagnostic and prognostic significance of exosomal miRNAs in TNBC treatment. Furthermore, we explore contemporary therapeutic approaches utilizing these exosomal miRNAs for the benefit of TNBC patients, shedding light on potential breakthroughs in TNBC management.

摘要

三阴性乳腺癌(TNBC)是一种具有挑战性且侵袭性强的乳腺癌形式,其治疗选择有限,预后较差。尽管化疗是主要的治疗方法,但耐药性常常阻碍治疗的成功。然而,对TNBC亚型和分子生物学认识的不断扩展为靶向治疗铺平了道路。值得注意的是,外泌体(细胞外囊泡)已成为参与肿瘤发生和耐药性的致癌因子的关键载体,促进细胞间通讯,并具有作为自我递送系统的潜力。在外泌体携带的物质中,微小RNA(miRNA)因其在转移后能够介导受体细胞表观遗传变化的能力而受到关注。研究已证实,与健康细胞相比,乳腺癌细胞中外泌体miRNA存在失调,这使其成为癌症诊断和预后有前景的生物标志物。在这篇全面综述中,我们总结了最新研究结果,这些结果强调了外泌体miRNA在TNBC治疗中的诊断和预后意义。此外,我们探索了利用这些外泌体miRNA造福TNBC患者的当代治疗方法,为TNBC治疗的潜在突破带来启示。

相似文献

1
Revolutionizing treatment for triple-negative breast cancer: Harnessing the power of exosomal miRNAs for targeted therapy.革新三阴性乳腺癌的治疗:利用外泌体微小RNA的力量进行靶向治疗。
Pathol Res Pract. 2023 Oct;250:154825. doi: 10.1016/j.prp.2023.154825. Epub 2023 Sep 16.
2
Exosomal miRNA profiles of triple-negative breast cancer in neoadjuvant treatment.新辅助治疗中三阴性乳腺癌的外泌体微小RNA谱
Oncol Lett. 2021 Dec;22(6):819. doi: 10.3892/ol.2021.13080. Epub 2021 Oct 5.
3
Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.GeparSixto 试验中接受新辅助治疗的三阴性和 HER2 阳性乳腺癌患者外泌体中的特定 microRNA 特征。
BMC Med. 2018 Oct 10;16(1):179. doi: 10.1186/s12916-018-1163-y.
4
Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease.三阴性乳腺癌微环境中的新型 miRNA 靶点和治疗方法:一种具有挑战性疾病的新兴希望。
Int J Mol Sci. 2020 Nov 24;21(23):8905. doi: 10.3390/ijms21238905.
5
Evaluation of exosomal miR-9 and miR-155 targeting PTEN and DUSP14 in highly metastatic breast cancer and their effect on low metastatic cells.评估高转移性乳腺癌中靶向 PTEN 和 DUSP14 的外泌体 miR-9 和 miR-155 及其对低转移性细胞的影响。
J Cell Biochem. 2019 Apr;120(4):5666-5676. doi: 10.1002/jcb.27850. Epub 2018 Oct 18.
6
Extracellular vesicles-associated miRNAs in triple-negative breast cancer: from tumor biology to clinical relevance.三阴性乳腺癌中外泌体相关 miRNA:从肿瘤生物学到临床相关性。
Life Sci. 2024 Jan 1;336:122332. doi: 10.1016/j.lfs.2023.122332. Epub 2023 Dec 8.
7
Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner.顺铂耐药 MDA-MB-231 细胞来源的外泌体以依赖外泌体 miR-423-5p 的方式增加受体细胞的耐药性。
Curr Drug Metab. 2019;20(10):804-814. doi: 10.2174/1389200220666190819151946.
8
Cellular and Exosomal MicroRNAs: Emerging Clinical Relevance as Targets for Breast Cancer Diagnosis and Prognosis.细胞和外泌体 microRNAs:作为乳腺癌诊断和预后靶点的临床新关联。
Adv Biol (Weinh). 2024 Apr;8(4):e2300532. doi: 10.1002/adbi.202300532. Epub 2024 Jan 22.
9
Upregulation of serum exosomal SUMO1P3 predicts unfavorable prognosis in triple negative breast cancer.血清外泌体 SUMO1P3 的上调预示着三阴性乳腺癌的不良预后。
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):154-160. doi: 10.26355/eurrev_202101_24379.
10
MicroRNAs Involved in Carcinogenesis, Prognosis, Therapeutic Resistance and Applications in Human Triple-Negative Breast Cancer.miRNAs 参与癌症发生、预后、治疗耐药及在三阴性乳腺癌中的应用
Cells. 2019 Nov 22;8(12):1492. doi: 10.3390/cells8121492.

引用本文的文献

1
Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells.乳腺癌与肿瘤微环境:免疫细胞的关键作用
Curr Oncol. 2025 Feb 28;32(3):143. doi: 10.3390/curroncol32030143.
2
Extracellular vesicles and their content in the context of polycystic ovarian syndrome and endometriosis: a review.多囊卵巢综合征和子宫内膜异位症背景下的细胞外囊泡及其内容物:综述。
J Ovarian Res. 2024 Aug 5;17(1):160. doi: 10.1186/s13048-024-01480-7.